Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol

Mizutani, Yoko; Mizutani, Yuki; Matsuyama, Katsuhiko; Kawamura, Miho; Fujii, Atsuhiro; Shu, En; Ohnishi, Hiroyuki; Seishima, Mariko

doi:10.1111/1346-8138.15355

Cited by 15 publications

(25 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[4][5][6][7][8][9][10][11][12] Among 10 IH patients of East Asian descent, seven had Summary of impetigo herpetiformis patients and IL36RN mutations…”

mentioning

confidence: 99%

Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases

Yoshikawa

Rokunohe

Kimura

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…[4][5][6][7][8][9][10][11][12] Among 10 IH patients of East Asian descent, seven had Summary of impetigo herpetiformis patients and IL36RN mutations…”

mentioning

confidence: 99%

Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases

Yoshikawa

Rokunohe

Kimura

et al. 2021

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…While there are several biologic agents available for the treatment of GPP in Japan, more robust data is needed to optimize the use of these agents in all patient types. Table 4 summarizes available evidence for the use of systemic treatments for GPP in different patient groups [1,[66][67][68][69][70][71][72][73][74][75][76]. To date, the approval of antagonists of IL-17 and IL-23 has been based on clinical trials that included mostly cases of moderate disease, so there is not adequate evidence to fully understand how these agents perform against GPP flares.…”

Section: Special Populations and Unmet Needsmentioning

confidence: 99%

“…TNF-α inhibitors are also suggested for lifethreatening disease on the basis of three case reports in pregnant or lactating women (Table 4) [66][67][68], and safety reports from the use of TNF-α inhibitors in pregnant women with other conditions. In our review of recent literature, we identified three further cases of successful treatment of GPP with TNF-α inhibitors during pregnancy [69,70]. Two of these cases were treated with certolizumab pegol, which, unlike adalimumab and infliximab, was not detected in cord serum or neonate serum [69,70].…”

Section: Pregnancymentioning

confidence: 99%

“…In our review of recent literature, we identified three further cases of successful treatment of GPP with TNF-α inhibitors during pregnancy [69,70]. Two of these cases were treated with certolizumab pegol, which, unlike adalimumab and infliximab, was not detected in cord serum or neonate serum [69,70]. However, these reports are not sufficient to fully evaluate their safety in pregnant women with GPP, and more data are needed.…”

Section: Pregnancymentioning

confidence: 99%

See 1 more Smart Citation

Generalized pustular psoriasis: current management status and unmet medical needs in Japan

Komine

Morita

2021

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Introduction: Generalized pustular psoriasis (GPP) is a rare, inflammatory skin disease characterized by recurrent flares of pustulation accompanied by systemic symptoms that can be life-threatening. The clinical and humanistic burden of GPP in Japan is high, and it is a designated intractable disease. We reviewed clinical evidence and guidelines for GPP treatment in Japan to identify unmet needs and assess data supporting the development and use of new targeted therapies. Areas covered: Using specific search terms in PubMed and Embase, with additional back-referencing, we retrieved literature related to GPP in Japan focusing on clinical and pathogenic characteristics, diagnosis, and treatment. Expert opinion: Although there are approved systemic therapies for GPP in Japan, all present uncertainties in terms of safety and efficacy. Clinical evidence supporting their use comes mostly from studies in patients with mild or moderate disease, and their effectiveness in treating acute phase GPP is unknown. The interleukin-36 pathway appears to be central to GPP pathogenesis. New therapies targeting this pathway show promise in patients presenting with acute phase GPP. The rarity and intermittent course of GPP make it challenging to recruit sufficient patients for trials and robustly investigate the efficacy and safety of these agents to treat GPP.

show abstract

“…We included three phase 3 trials (i.e., Measure Up 1, Measure Up 2, and AD Up) from two publications. 1,2 All the included trials were studies with low risk of bias (Fig. 1a).…”

mentioning

confidence: 99%

Therapy‐refractory folliculitis decalvans treated with certolizumab pegol

Hoy

Böhm

2021

Int J Dermatology

View full text Add to dashboard Cite

week 16, EASI-75 at week 2, WP-NRS response at week 16, WP-NRS response at week 4, and WP-NRS response at week 1; and these eight safety outcomes of interest were any treatmentemergent adverse event (TEAE), serious adverse events (SAE), adverse events leading to discontinuation of study drug (AELD), acne, upper respiratory tract infection (URTI), nasopharyngitis, headache, and plasma creatine phosphokinase elevation (PCPE). Random-effects network meta-analysis was conducted

show abstract

Generalized pustular psoriasis in pregnancy, successfully treated with certolizumab pegol

Cited by 15 publications

References 5 publications

Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases

Significance of IL36RN mutation analyses in the management of impetigo herpetiformis: A case report and review of published cases

Generalized pustular psoriasis: current management status and unmet medical needs in Japan

Therapy‐refractory folliculitis decalvans treated with certolizumab pegol

Contact Info

Product

Resources

About